Skip to main content

Table 1 Demographics of Participants in VIRUS Registry by AKI status

From: SARS-CoV-2 infection increases risk of acute kidney injury in a bimodal age distribution

  Total No AKI AKI
6874 4155 (60.5) 2719 (39.6)
Age, years, median (IQR) 60 (44–71) 55 (39–68) 65 (53–75)
Age Categories
  < 20 years 621 (9) 450 (11) 171 (6)
 20 to < 40 years 772 (11) 615 (15) 157 (6)
 40 to < 60 years 2038 (30) 1359 (33) 679 (25)
 60 to < 80 years 2647 (39) 1375 (33) 1272 (47)
  ≥ 80 years 796 (12) 356 (9) 440 (16)
BMI categorya
 Underweight 137 (2) 78 (2) 59 (2)
 Normal 1270 (19) 832 (20) 438 (16)
 Overweight 1620 (24) 965 (23) 655 (24)
 Obesity 1666 (24) 921 (22) 745 (27)
 Severe Obesity 552 (8) 302 (7) 250 (9)
Unknown 1629 (24) 1057 (25) 572 (21)
Sex (male)b 3998 (58) 2327 (56) 1671 (62)
Race/Ethnicityb
 White, non-Hispanic 2189 (32) 1273 (31) 916 (34)
 White, Hispanic 523 (8) 335 (8) 188 (7)
 Black, non-Hispanic 1353 (20) 700 (17) 653 (24)
 Black, Hispanic 50 (0.7) 37 (0.9) 13 (0.5)
 Asian American 95 (1) 53 (1) 42 (2)
 South Asian 1027 (15) 842 (20) 185 (7)
 East Asian 36 (0.5) 20 (0.5) 16 (0.6)
 West Asian 106 (2) 61 (2) 45 (2)
 Other/mixed 845 (12) 511 (12) 334 (12)
 White, ethnicity not specified 402 (6) 184 (4) 218 (8)
 Black, ethnicity not specified 76 (1) 36 (0.9) 40 (2)
Location of Center
 United States 4984 (73) 2872 (69) 2112 (78)
 Non-United States 1890 (28) 1283 (31) 607 (22)
Number of Comorbidities, median (IQR) 2 (1, 4) 2 (1, 4) 3 (1, 5)
Healthy (no comorbidities) 1356 (20) 1020 (25) 336 (12)
Comorbiditiesc
 Hypertension 3404 (50) 1722 (41) 1682 (62)
 Diabetes 2279 (33) 1169 (28) 1110 (41)
 Heart Disease 1577 (23) 732 (18) 845 (31)
Chronic Kidney Disease 754 (11) 339 (8) 415 (15)
 Asthma 757 (11) 478 (12) 279 (10)
 Chronic lung disease, not asthma 1395 (20) 770 (19) 625 (23)
 Stroke/ Neurological disorder 818 (12) 447 (11) 371 (14)
 Cancer 904 (13) 497 (12) 407 (15)
Pre-Hospital Medications
 ACE-I/ARBs 1497 (22) 756 (18) 741 (27)
 Diuretics 179 (3) 77 (2) 102 (4)
 NSAIDs 610 (9) 377 (9) 233 (9)
 Aspirin 1127 (16) 554 (13) 573 (21)
Severity of Diseased
 Mild disease 2710 (39) 1950 (47) 760 (28)
 Moderate disease 2064 (30) 1389 (33) 675 (25)
 Severe disease 2100 (31) 816 (20) 1284 (47)
Ever admitted to ICU (yes) 4075 (59) 2149 (52) 1926 (71)
SARS-CoV2 Testing
 PCR+ 6409 (93) 3858 (93) 2551 (94)
 Antibody+ 98 (1) 45 (1) 53 (2)
 PCR and antibody+ 367 (5) 252 (6) 115 (4)
  1. Data presented as number (column percentile), except where specified. ACE-I = angiotensin-converting enzyme-inhibitors; AKI Acute kidney injury, ARB Angiotensin receptor blockers, BMI Body mass index, ECMO Extracorporeal membrane oxygenation, ICU Intensive care unit, IQR Interquartile range, NSAID Non-steroidal anti-inflammatory drugs, PCR Polymerase chain reaction, VIRUS Viral Infection and Respiratory Illness Universal Study
  2. aBMI Category defined by CDC. Weight-for-height percentiles used for those < 2 years of age, BMI percentiles used for those 2–17 years of age and categorized as underweight for < 5%, normal for 5–85%, overweight for 85–95%, obesity for > 95%. BMI categories for those ≥18 years of age defined as underweight <BMI 18.5, normal BMI 18.5- < 25, overweight BMI 25- < 30, obesity BMI 30- < 40, and severe obesity BMI ≥ 40
  3. bMissing data: Sex missing for 1 participant. Race/ethnicity data missing for 172 participants
  4. cMultiple comorbidities allowed. Most common ones presented. Heart disease defined as heart failure, coronary artery disease, arrythmias, valvular disease
  5. dSeverity of disease is defined as: severe disease is a composite of the use of invasive organ support therapy (ventilation, use of vasopressor(s) and/or inotrope(s), and/or use of ECMO); moderate disease is defined as patient admitted to an ICU but did not have any of the invasive organ support therapies as defined for severe disease; and mild disease is defined as neither an ICU admission nor invasive organ support therapies for severe disease